RT Journal Article
SR Electronic
T1 Oxylipin profiling identifies a mechanistic signature of metabolic syndrome: results from two independent cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.04.22271895
DO 10.1101/2022.03.04.22271895
A1 Dalle, Céline
A1 Tournayre, Jérémy
A1 Mainka, Malwina
A1 Basiak-Rasała, Alicja
A1 Pétéra, Mélanie
A1 Lefèvre-Arbogast, Sophie
A1 Dalloux-Chioccioli, Jessica
A1 Deschasaux-Tanguy, Mélanie
A1 Lécuyer, Lucie
A1 Kesse-Guyot, Emmanuelle
A1 Fezeu, Léopold
A1 Hercberg, Serge
A1 Galan, Pilar
A1 Samieri, Cécilia
A1 Zatońska, Katarzyna
A1 Calder, Philip C.
A1 Hjorth, Mads Fiil
A1 Astrup, Arne
A1 Mazur, André
A1 Bertrand-Michel, Justine
A1 Schebb, Nils H.
A1 Szuba, Andrzej
A1 Touvier, Mathilde
A1 Newman, John W.
A1 Gladine, Cécile
YR 2022
UL http://medrxiv.org/content/early/2022/03/07/2022.03.04.22271895.abstract
AB Background Metabolic syndrome (MetS) is a complex condition encompassing a constellation of cardiometabolic abnormalities. Integratively phenotyping the molecular pathways involved in MetS would help to deeply characterize its pathophysiology and to better stratify the risk of cardiometabolic diseases. Oxylipins are a superfamilly of lipid mediators regulating most biological processes involved in cardiometabolic health.Methods A high-throughput validated mass spectrometry method allowing the quantitative profiling of over 130 oxylipins was applied to identify and validate the oxylipin signature of MetS in two independent case/control studies involving 476 participants.Results We have uncovered and validated an oxylipin signature of MetS (coined OxyScore) including 23 oxylipins and having high performances of classification and replicability (cross-validated AUCROC of 89%, 95% CI: 85%-93% and 78%, 95% CI: 72%-85% in the Discovery and Replication studies, respectively). Correlation analysis and comparison with a classification model incorporating both the oxylipins and the MetS criteria showed that the oxylipin signature brings consistent and complementary information supporting its clinical utility. Moreover, the OxyScore provides a unique mechanistic signature of MetS regarding the activation and/or negative feedback regulation of crucial molecular pathways that may help identify patients at higher risk of cardiometabolic diseases.Conclusion Oxylipin profiling identifies a mechanistic signature of metabolic syndrome that may help to enhance MetS phenotyping and ultimately to better predict the risk of cardiometabolic diseases via a better patient stratification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by national research agencies: French grant ANR.16.HDHL.0004.01/02, German BMBF grant 01EA1702, Danish grant 4203.00006B and Polish grant ERAH.E220.18.001 in the framework of the Oxygenate project supported by the European Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL). And USDA CRIS Project 2032.51530.025.00D.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PURE study was approved by the Institutional Review Board of the Wroclaw Medical University (IRB number: KB-443/2006). NutriNet-Sante study was approved by the International Research Board of the French Institute of Health and Medical research (IRB Inserm nb 0000388FWA00005831) and the Comite National Informatique et Liberte (CNIL 908450 and 909216).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authorAAarachidonic acidAHEIalternative healthy eating indexALAα-linolenic acidAUCROCarea under the receiver operating characteristic curvesBHBenjamini-HochbergBHTbutylated hydroxytolueneBMIbody mass indexBPblood pressureCADcoronary artery diseaseCOXcyclooxygenaseCYPcytochrome P450DGLAdihomo-γ-linolenic acidDHAdocosahexaenoic acidEDTAEthylenediaminetetraacetic acidEPAeicosapentaenoic acidFAMEsfatty acids methyl estersFFQfood frequency questionnaireGCgas chromatographyHDLchigh density lipoprotein cholesterolLAlinoleic acidLASSOleast absolute shrinkage and selection operatorLCliquid chromatographyLDLclow density lipoprotein cholesterolLOXlipoxygenaseMeOHmethanolMetSmetabolic syndromeMRMmultiple reaction monitoringMSmass spectrometryMS/MStandem mass spectrometryOAoleic acidORodd ratioPMNpolymorphonuclearPPARγproliferator-activated receptor γPUFAspolyunsaturated fatty acidsPUREProspective Urban and Rural EpidemiologicalQCquality controlSDstandard deviationsEHsoluble epoxide hydrolaseSPEsolid phase extractionTGtriglyceridesVLDLvery density lipoprotein cholesterolWCwaist circumference.